Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single InstitutionJuan Pablo Alderuccio, Izidore S. Lossos, Wei Zhao et al.|Journal of Clinical Oncology|2018Cited by 79
The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer GrowthEdward B. Garon, Dennis J. Slamon, Richard S. Finn et al.|Molecular Cancer Therapeutics|2013Cited by 64
Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphomaBrian T. Hill, Brad S. Kahl, Loretta J. Nastoupil et al.|British Journal of Haematology|2018Cited by 51
Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentationJuan Pablo Alderuccio, Izidore S. Lossos, Wei Zhao et al.|American Journal of Hematology|2019Cited by 36
Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall SurvivalAllison Winter, Brian T. Hill, Loretta J. Nastoupil et al.|Blood|2018Cited by 10